Pierre Caloz Sells 9,455 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QUREGet Free Report) COO Pierre Caloz sold 9,455 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

uniQure Trading Down 0.9 %

Shares of QURE stock traded down $0.06 during trading hours on Wednesday, hitting $6.69. 1,042,023 shares of the company were exchanged, compared to its average volume of 938,775. The firm has a market cap of $319.85 million, a P/E ratio of -1.39 and a beta of 1.03. uniQure has a fifty-two week low of $5.19 and a fifty-two week high of $22.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.88 and a current ratio of 10.11. The company has a 50 day simple moving average of $6.10 and a two-hundred day simple moving average of $6.78.

Analysts Set New Price Targets

Several equities analysts recently commented on QURE shares. Mizuho downgraded shares of uniQure from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $52.00 to $10.00 in a research note on Tuesday, December 19th. The Goldman Sachs Group boosted their target price on shares of uniQure from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of uniQure in a report on Wednesday, December 20th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of uniQure in a report on Friday, January 19th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 price target on shares of uniQure in a research report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.17.

Read Our Latest Analysis on QURE

Hedge Funds Weigh In On uniQure

Institutional investors have recently modified their holdings of the company. BluePath Capital Management LLC bought a new stake in shares of uniQure during the third quarter worth about $27,000. Roffman Miller Associates Inc. PA purchased a new position in shares of uniQure during the second quarter valued at approximately $30,000. Headlands Technologies LLC bought a new position in shares of uniQure during the third quarter valued at about $31,000. Captrust Financial Advisors lifted its position in shares of uniQure by 1,392.3% during the second quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 1,810 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of uniQure by 152.5% during the first quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,231 shares in the last quarter. 73.87% of the stock is owned by institutional investors and hedge funds.

About uniQure

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease.

See Also

Insider Buying and Selling by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.